Therapeutic Strategies against Neurodegenerative Conditions (TSANC)
Venue: The Boston Marriott
Location: Burlington, Massachusetts, United States
Event Date/Time: Oct 10, 2005 | End Date/Time: Oct 10, 2005 |
Early Registration Date: Sep 10, 2005 | |
Abstract Submission Date: Sep 10, 2006 |
Description
The conference focuses on the latest and most exciting research findings in the identification of novel molecular targets and the development of potential therapeutic strategies for neurodegenerative conditions. We have an excellent list of speakers from academia, industry and government whose presentations will cover a range of topics within the area of neurodegeneration and therapy and with information from cell culture models to clinical trials.
The conference will take place in Boston on Monday, October 10 and Tuesday, October 11. Please bring this conference to the attention of your colleagues, post-doctoral fellows and students who may benefit from attending the meeting. Please register early and submit an abstract. Come to Boston earlier or stay later and enjoy the many historic and cultural delights of this beautiful city.
It will be my pleasure to welcome you to the first annual conference on Therapeutic Strategies against Neurodegenerative Conditions in Boston.
Sincerely,
Santosh R. D'Mello, Ph.D.
Conference Chairperson
Venue
Additional Information
DAY 1 - Monday, October 10, 2005 |
|
7:15 | Registration and Breakfast |
8:15 | Opening Remarks |
8:30 | Neuroprotective Approaches to Alzheimer's Disease |
John Davis, | |
GlaxoSmithKline | |
9:00 | Amyloid-based Therapeutic Strategies for Alzheimer's Disease |
Rusell Rydel, Ph.D., Vice President, Pharmacology | |
Elan Pharmaceuticals | |
9:30 | Drug Development Targets and Strategies for Neuroprotection and Neurorestoration in Alzheimer's Disease |
Martin Tolar, M.D., Ph.D, Director, Clinical Strategic Partnerships | |
Pfizer Global Research | |
10:00 | APOE4 and Alzheimer's Disease: From Susceptibility Gene Variant to Clinical Trial to New Drug Discovery |
Ann Saunders, Ph.D., Therapy Area Team Leader, Metabolic & Viral Diseases | |
GlaxoSmithKline | |
10:30 | Refreshment Break and Exhibiting |
11:00 | KEYNOTE SPEAKER |
Steve M. Paul, Executive Vice President, Lilly Research Labs | |
Eli Lilly & Co. | |
12:00 | Lunch |
1:00 | Parkinson's Disease: Mechanisms and Models |
Serge Przedborski, M.D., Ph.D., Professor, Center for Neurology and Behavior | |
Columbia University College of Physicians and Surgeons | |
1:30 | The Therapeutic Potential of Metabotropic Glutamate Receptor Ligands in the Treatment of Neurodegenerative Disease |
Michael Marino, Ph.D., Neuroscience Drug Discovery, Movement Disorders | |
Merck Research Labs | |
2:00 | The Role of Iron and Glutathione in Parkinson's Disease: Toward Rational Therapeutics |
Julie Andersen, Ph.D., Professor | |
Bucks Institute for Age Research | |
2:30 | Neuroprotection and Neurorepair: Small Molecule Approaches for Parkinson's Disease |
Michael J. O'Neill, Principal Research Scientist/Team and Project Leader, Neurodegeneration Group, | |
Eli Lilly (UK) | |
3:00 | Refreshment Break and Exhibiting |
3:30 | Therapeutic Strategies for the Disease Modification of Alzheimer's Disease |
J. Steven Jacobsen, Ph.D., Associate Director, Neuroscience | |
Wyeth Research | |
4:00 | TBA |
Mark A. Findeis, Ph.D., Vice President of Research | |
Satori Pharmaceuticals, Inc. | |
4:30 | TBA |
David A. Lowe, Chief Scientific Officer | |
Memory Pharmaceuticals Corporation | |
5:30 | Networking Reception |
DAY 2 - Tuesday, October 11, 2005 | |
7:15 | Registration and Breakfast |
8:15 | Recap of Day 2 |
8:30 | Signal Transduction |
Zewei Huang, Ph.D., Professor | |
The Burnham Institute | |
9:00 | A Delicate Balance: Neuronal Life and Death |
Carol Troy, M.D., Ph.D, Associate Professor of Clinical Pathology and Neurology | |
Taub Center for the Study of Alzheimer's Disease and the Aging Brain | |
Columbia University College of Physicians and Surgeons | |
9:30 | Regulatory Pathways that Control Repair and Regeneration |
Lee Rubin, Ph.D., Executive Vice President of Research and Chief Scientific Officer | |
Curis, Inc. | |
10:00 | The Transcription Factors Activated by Oxidative Stress that May Mediate Protective or Deleterious Responses |
Rajiv Ratan, M.D., Ph.D, Neurology | |
Beth Israel Deaconess Medical Center, Harvard Medical School | |
10:30 | Refreshment Break and Exhibiting |
11:00 | KEYNOTE SPEAKER |
Kevin A. Roth, M.D., Ph.D., Director, Neuropathology | |
University of Alabama at Birmingham | |
12:00 | Lunch |
1:00 | Neurodegeneration Approved Drug Screening and Therapeutics Development |
Jill Heemskerk, Ph.D., Program Director, Technology Development | |
National Institute of Neurological Disorders and Stroke, NIH | |
1:30 | Neuroprotection by 3' Substituted Indolones |
Santosh R. D'Mello, Ph.D., Professor, Dept of Molecular & Cell Biology | |
University of Texas at Dallas | |
2:00 | Therapeutic Potential fo Supressing CPK's |
David Park, M.D. | |
University of Ottowa | |
2:30 | Potential Use of Mood Stabilizing Drugs for Neurodegenerative Diseases |
De-Maw Chuang, Ph.D., Chief, Section on Molecular Neurobiology | |
National Institute of Mental Health, National Institutes of Health | |
3:00 | Refreshment Break and Exhibiting |
3:30 | TBA |
James Wang | |
En Vivo | |
4:00 | TBA |
Barbara Slusher, Ph.D., Senior Vice President, Research | |
Guilford Pharmaceuticals | |
4:30 | Oral Presentations of Selected Abstracts |
To Be Announced on the GTCbio Website | |
5:00 | Conference Concludes |